Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page revision label was updated to v3.6.3, and older revision text along with links such as 'Bladder cancer' and 'MedlinePlus Genetics' were removed.SummaryDifference0.2%

- Check16 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0. This reflects a minor version update to the page template.SummaryDifference0.1%

- Check30 days agoChange DetectedRecruitment status shows no longer looking for participants. New user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) have been added, the Intervention/Treatment header formatting updated (from 'Intervention / Treatment' to 'Intervention/Treatment'), and the revision tag updated to v3.6.0.SummaryDifference0.5%

- Check38 days agoChange DetectedThe page footer now displays Revision: v3.5.5, replacing the previous Revision: v3.5.4. This indicates a small software update to the site.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page no longer displays links or sections for bladder cancer, related topics, and MedlinePlus Genetics, reducing navigational references to these topics on the study page.SummaryDifference0.2%

- Check52 days agoChange DetectedNew navigation items were added to the page: 'Bladder cancer' and a 'related topics' section featuring 'MedlinePlus Genetics', providing additional context and links to related resources.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.